Deterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritis

BMJ Case Reports

Volumn , Issue , 2009, Pages

  Kuo, Shu Chen ^a   Lee, Hui Ting ^a   Chen, Wei Sheng ^a   Chou, Chung Tei ^a   Tsai, Chang Youh ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897585974     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.09.2008.0873     Document Type: Article

References (11)

1. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV screening? World J Gastroenterol 2006; 12: 974-6.Author: is this 6 months in total or 6 months per incident? [Medline] [Web of Science]
2. Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after inf liximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003; 30: 1624-5. [Abstract/FREE Full text] (Pubitemid 36835467)
3. Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5. [Abstract/FREE Full text] (Pubitemid 39120128)
4. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-7. [FREE Full text] (Pubitemid 36760576)
5. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31: 107-9. [Abstract/FREE Full text] (Pubitemid 38067531)
6. Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788-9. [FREE Full text] (Pubitemid 40559316)
7. Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7. [CrossRef] [Medline] [Web of Science]
8. Carroll MB, Bond MI. Use of tumor necrosis factor-α inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008; 38: 208-17. [CrossRef] [Medline] [Web of Science]
9. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-α therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006; 45: 1294-7. [Abstract/FREE Full text] (Pubitemid 44542073)
10. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-9. [Abstract/FREE Full text] (Pubitemid 44133258)
11. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 21: 1366-71. [Medline] [Web of Science] (Pubitemid 44154702)